11 Citations (Scopus)

Abstract

Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-range, high energy α-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.

Original languageEnglish (US)
Pages (from-to)639-650
Number of pages12
JournalCancer Biotherapy and Radiopharmaceuticals
Volume28
Issue number9
DOIs
StatePublished - Nov 1 2013

Fingerprint

Radioimmunotherapy
Neoplasms
Immunoconjugates
Residual Neoplasm
Radioisotopes
Pharmacokinetics
Antigens
Therapeutics

Keywords

  • animal model
  • antibody
  • radioimmunotherapy
  • radiopharmaceuticals
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Emerging trends for radioimmunotherapy in solid tumors. / Jain, Maneesh; Gupta, Suprit; Kaur, Sukwinder; Palanimuthu Ponnusamy, Moorthy; Batra, Surinder Kumar.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 28, No. 9, 01.11.2013, p. 639-650.

Research output: Contribution to journalReview article

@article{fb84625c8dbc41acb301927f837f64ea,
title = "Emerging trends for radioimmunotherapy in solid tumors",
abstract = "Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-range, high energy α-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.",
keywords = "animal model, antibody, radioimmunotherapy, radiopharmaceuticals, targeted therapy",
author = "Maneesh Jain and Suprit Gupta and Sukwinder Kaur and {Palanimuthu Ponnusamy}, Moorthy and Batra, {Surinder Kumar}",
year = "2013",
month = "11",
day = "1",
doi = "10.1089/cbr.2013.1523",
language = "English (US)",
volume = "28",
pages = "639--650",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Emerging trends for radioimmunotherapy in solid tumors

AU - Jain, Maneesh

AU - Gupta, Suprit

AU - Kaur, Sukwinder

AU - Palanimuthu Ponnusamy, Moorthy

AU - Batra, Surinder Kumar

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-range, high energy α-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.

AB - Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-range, high energy α-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.

KW - animal model

KW - antibody

KW - radioimmunotherapy

KW - radiopharmaceuticals

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84885581424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885581424&partnerID=8YFLogxK

U2 - 10.1089/cbr.2013.1523

DO - 10.1089/cbr.2013.1523

M3 - Review article

C2 - 23844555

AN - SCOPUS:84885581424

VL - 28

SP - 639

EP - 650

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 9

ER -